Brusatol-induced HL-60 cell differentiation involves NF-κB activation

Cancer Letters

Volumn 206, Issue 1, 2004, Pages 43-50

  Cuendet, Muriel ^a   Gills, Joell J ^a   Pezzuto, John M ^a,b,c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

Brusatol; Cell differentiation; NF B

Indexed keywords

BRUSATOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ARTICLE; CELL DIFFERENTIATION; CELL LYSATE; CONTROLLED STUDY; DNA DETERMINATION; DRUG MECHANISM; ELECTROPHORETIC MOBILITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PHOSPHORYLATION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; UPREGULATION;

CELL DIFFERENTIATION; CELL NUCLEUS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HL-60 CELLS; HUMANS; I-KAPPA B PROTEINS; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEPTIDES; PROTEIN TRANSPORT; QUASSINS;

BRUCEA JAVANICA;

EID: 1442335376     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2003.11.011     Document Type: Article

References (26)

1. Sachs L. Constitutive uncoupling of pathways of gene expression that control growth and differentiation in myeloid leukemia: a model for the origin and progression of malignancy. Proc. Natl Acad. Sci. USA. 77:1980;6152-6156.
2. Huang M.-E., Ye Y.-C., Chen S.-R., Chai J.-R., Lu J.-X., Lin Z., et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 72:1988;567-572.
3. Warrell R.P., de The H., Wang Z.-W., Degos L. Acute promyelocytic leukemia. N. Engl. J. Med. 329:1993;177-189.
4. Sen R., Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein NF-κB by a posttranslational mechanism. Cell. 47:1986;921-928.
5. Baldwin A.S. The NF-κB and IκB proteins: new discoveries and insights. Annu. Rev. Immunol. 14:1996;649-683.
6. Schmitz M.L., Baeuerle P.A. The p65 subunit is responsible for the strong transcription activating potential of NF-κB. Eur. Mol. Biol. Org. J. 10:1991;3805-3817.
7. May M.J., Ghosh S. Signal transduction through NF-κB. Immunol. Today. 19:1998;80-88.
8. Baeuerle P.A., Henkel T. Function and activation of NF-κB in the immune system. Annu. Rev. Immunol. 12:1994;141-179.
9. Baichwal V.R., Baeuerle P.A. Activate NF-κB or die? Curr. Biol. 7:1997;R94-R96.
10. Siebenlist U. NF-κB/IκB proteins. Their role in cell growth, differentiation and development. Biochim. Biophys. Acta. 1332:1997;R7-R13.
11. Snapper C.M., Zelazowski P., Rosas F.R., Kehry M.R., Tian M., Baltimore D., Sha W.C. B cells from p50/NF-κB knockout mice have selective defects in proliferation, differentiation, germ-line CH transcription, and Ig class switching. J. Immunol. 156:1996;183-191.
12. Feng Z., Porter A.G. NF-κB/Rel proteins are required for neuronal differentiation of SH-SY5Y neuroblastoma cells. J. Biol. Chem. 274:1999;30341-30344.
13. Tang W., Eisenbrand G. Brucea javanica (L.). Tang W., Eisenbrand G. Chinese Drugs of Plant Origin: Chemistry, Pharmacology, and Use in Traditional and Modern Medicine. 1992;207-222 Springer, Berlin.
14. Liao L.L., Kupchan S.M., Horwitz S.B. Mode of action of the antitumor compound bruceantin, an inhibitor of protein synthesis. Mol. Pharmacol. 12:1976;167-176.
15. Fresno M., Gonzales A., Vazquez D., Jimenez A. Bruceantin, a novel inhibitor of peptide bond formation. Biochem. Biophys. Acta. 518:1978;104-112.
16. Suh N., Luyengi L., Fong H.H.S., Kinghorn A.D., Pezzuto J.M. Discovery of natural product chemopreventive agents utilizing HL-60 cell differentiation as a model. Anticancer Res. 15:1995;233-240.
17. Luyengi L., Suh N., Fong H.H.S., Kinghorn A.D., Pezzuto J.M. A lignan and four terpenoids from Brucea javanica that induce differentiation with cultured HL-60 promyelocytic leukemia cells. Phytochemistry. 43:1996;409-412.
18. 1 arrest is associated with down-regulation of c-myc. Leukemia. 16:2002;2275-2284.
19. Cuendet M., Christov K., Lantvit D.D., Deng Y., Hedayat S., Helson L., et al. Multiple myeloma regression mediated by bruceantin. Clin. Cancer Res. 2003;. in press.
20. Bedikian A.Y., Valdivieso M., Bodey G.P., Murphy W.K., Freireich E.J. Initial clinical studies with bruceantin. Cancer. Treat. Rep. 63:1979;1843-1847.
21. Richon V.M., Webb Y., Merger R., Sheppard T., Jursic B., Ngo L., et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl Acad. Sci. USA. 93:1996;5705-5708.
22. Gills J. Chemotherapeutic Potential of Deguelin and Evaluation of New Agents for Skin Cancer Chemoprevention. 2003;Department of Medicinal Chemistry and Pharmacognosy, University of Illinois, Chicago, IL.
23. Hall I.H., Lee K.H., Eigebaly S.A., Imakura Y., Sumida Y., Wu R.Y. Antitumor agents XXXIV: mechanism of action of bruceoside A and brusatol on nucleic acid metabolism of P-388 lymphocytic leukemia cells. J. Pharm. Sci. 68:1979;883-887.
24. Ammon C., Mondal K., Andreesen R., Krause S.W. Differential expression of the transciption factor NF-κB during human mononuclear phagocyte differentiation to macrophages and dendritic cells. Biochem. Biophys. Res. Commun. 268:2000;99-105.
25. s and Bax contributes to cytochrome c release in cyanide-induced apoptosis. J. Neurochem. 81:2002;842-852.
26. Dirsch V.M., Gerbes A.L., Vollmar A.M. Ajoene, a compound of garlic, induces apoptosis in human promyeloleukemic cells, accompanied by generation of reactive oxygen species and activation of nuclear factor κB. Mol. Pharmacol. 53:1998;402-407.